Literature DB >> 15222976

An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA.

David H Dreyfus1, Agniesczka Matczuk, Ramsay Fuleihan.   

Abstract

RNA oligonucleotides termed External Guide Sequence (EGS) and RNAi have been described that target specific gene expression by site-specific cleavage of mRNA. EGS serve as an RNA catalyst or ribozyme by directing bound mRNA to the ubiquitous cellular enzyme RNAse P. We describe an EGS targeting human interleukin (IL)-4 receptor alpha mRNA, an important cytokine receptor in the pathogenesis of asthma and allergic disease expressed in pulmonary tissues. This EGS was designed to explore pulmonary delivery of catalytic RNA oligonucleotides as a novel therapy in asthma and other atopic diseases. Inhaled DNA oligonucleotides termed Respirable Antisense OligoNucleotide Sequences (RASONS) are selectively internalized in lung tissues in a complex with endogenous lipid surfactants present in normal lung and can alter pulmonary gene expression. Potential applications of inhaled RNA oligonucleotides in therapy of pulmonary and related systemic diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222976     DOI: 10.1016/j.intimp.2004.03.012

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Inhibition of no tail (ntl) gene expression in zebrafish by external guide sequence (EGS) technique.

Authors:  De-Sheng Pei; Yong-Hua Sun; Yong Long; Zuo-Yan Zhu
Journal:  Mol Biol Rep       Date:  2007-02-09       Impact factor: 2.316

2.  Inactivation of expression of two genes in Saccharomyces cerevisiae with the external guide sequence methodology.

Authors:  Xudong Cheng; Jae-Hyeong Ko; Sidney Altman
Journal:  RNA       Date:  2011-01-13       Impact factor: 4.942

Review 3.  External guide sequence technology: a path to development of novel antimicrobial therapeutics.

Authors:  Carol Davies-Sala; Alfonso Soler-Bistué; Robert A Bonomo; Angeles Zorreguieta; Marcelo E Tolmasky
Journal:  Ann N Y Acad Sci       Date:  2015-04-09       Impact factor: 5.691

Review 4.  The future of antisense oligonucleotides in the treatment of respiratory diseases.

Authors:  Marina Ulanova; Alan D Schreiber; A Dean Befus
Journal:  BioDrugs       Date:  2006       Impact factor: 5.807

5.  Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).

Authors:  David H Dreyfus; S Mark Tompkins; Ramsay Fuleihan; Lucy Y Ghoda
Journal:  Biologics       Date:  2007-12

6.  A review of antisense therapeutic interventions for molecular biological targets in asthma.

Authors:  Florin-Dan Popescu; Florica Popescu
Journal:  Biologics       Date:  2007-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.